Navigation Links
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Date:7/2/2009

ltaq(R) for patients in a therapeutic area that has seen few new treatment options in the last twenty years," said Marc Cluzel, MD, Senior Vice President, Research and Development, sanofi-aventis. "Sanofi-aventis' commitment to research and development in this area is rewarded today, and we hope it will benefit many patients suffering from this disease."

The incidence of atrial fibrillation is growing worldwide in relation to aging populations. It is emerging as a public health concern and affects about 2.5 million people in the United States and 4.5 million people in the European Union. Atrial fibrillation is a potentially life-threatening condition, with significant burden on patients, health care providers and payers.

"It is exciting that Multaq(R) will now be available as a treatment option for patients with paroxysmal or persistent atrial fibrillation or atrial flutter," said Stuart Connolly, M.D., Professor of Medicine & Director, Division of Cardiology, McMaster University, Hamilton, Canada, and co-principal investigator in the ATHENA study. "Based on clinical studies, Multaq(R) reduces the risk of cardiovascular hospitalizations in patients with atrial fibrillation / atrial flutter, this outcome could change the way we approach the management of the disease."

Multaq(R) is to be given twice daily as a 400 mg tablet and should be taken as one tablet with the morning and evening meals. Treatment with Multaq(R) can be initiated in an outpatient setting. Most common adverse reactions are diarrhea, nausea, vomiting, abdominal pain, asthenia (weakness) and cutaneous rash.

A registration dossier of Multaq(R) is also under regulatory review by the European Medicines Agency (EMEA).

About dronedarone (Multaq(R))

Multaq(R), discovered and developed by sanofi-aventis, is one of the major therapeutic i
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
2. FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
3. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
4. ClearWay Minnesota(SM) Board Approves Four Regional Grants
5. Department of Defense Approves ISSA as Fitness Education Provider to Military Spouses
6. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
7. Treating Untreatable Brain Tumors: FDA Approves New Laser Surgery
8. FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets
9. Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill
10. Kaiser Permanente Approves $13 Million in Community Benefit Grants in First Quarter of 2009
11. FDA Approves Plan B Pill for 17-Year-Olds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... 2015 , ... An article published August 19th by the LA ... through to open a pizzeria in Westchester. Mr. LaRocco was aware from opening prior ... but the current process, having already gone on for over a year, is taking ...
(Date:8/28/2015)... Church, VA (PRWEB) , ... ... ... Cybersecurity Risk Management for Medical Devices:, Understanding the FDA’s Position and Best ... Rockville, MD, http://www.fdanews.com/cybersecuritymd , This workshop, chaired by internationally renowned ...
(Date:8/28/2015)... ... 2015 , ... On May 30th, 2015, Best Drug Rehabilitation, a results-based substance ... A Mission” benefit concert in Mendon, IL. Held in the Show Barn at the ... music education programs in the underfunded local school districts of Mendon at neighboring Quincy, ...
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was ... the latest and coolest applications on the market for iOS, Android, and Windows. Joe ... with viewers how this software allows businesses to track product movement from beginning to ...
(Date:8/28/2015)... , ... August 28, 2015 , ... Medical Solutions, one ... 2015 Best Places to Work in Healthcare by Modern Healthcare and will be ... , Now in its eighth year, the Best Places to Work in Healthcare program ...
Breaking Medicine News(10 mins):Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3
... What: Georgetown,s Lombardi Comprehensive Cancer Center and Capital Breast ... of providing breast cancer screening to underserved women at ... DC. This is the second year the AVON Foundation ... Capital Breast Care Center to their dedication to breast ...
... May 1, Binax, Inc., a leading provider ... identify the causative pathogens of infectious diseases, announced that it ... to customers and potential customers of the BinaxNow(R) Influenza A ... A & B test has not been validated for detection ...
... greatly improved when doctors implemented a series of ... unit. Yale School of Medicine researchers report their ... American Journal of Obstetrics & Gynecology . ... determine if improving communication between medical staff and ...
... malignancies among older men , , FRIDAY, May 1 ... chronic kidney disease appear to have a higher risk ... Australian scientists report. , The observation -- which suggests ... cancer, but not prostate cancer -- adds to previous ...
... HAMILTON, Bermuda, May 1 Warner Chilcott Limited (Nasdaq: ... its subsidiaries and Mayne Pharma International Pty. Ltd. ("Mayne") ... and Mylan Inc. ("Mylan") in the District Court for ... U.S. Patent No. 6,958,161 (the ",161 Patent") which covers ...
... have embraced a simple and direct model of the disease ... bearing total responsibility for the spread of cancer to distant ... grew, and reproduced. The result was a seed-dominant model that ... tumor seed but neglecting the role of the soil. , ...
Cached Medicine News:Health News:Lombardi Cancer Center and the Capital Breast Care Center awarded $750,000 from the AVON Foundation 2Health News:Obstetrical unit at Yale-New Haven Hospital achieves dramatic improvement in patient safety 2Health News:Chronic Kidney Disease Raises Risk for Some Cancers 2Health News:Chronic Kidney Disease Raises Risk for Some Cancers 3Health News:Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent 2Health News:Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent 3Health News:Where tumor cells boldly go: Weill Cornell cancer biologists shed light on the metastatic niche 2
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by AstraZeneca plc, ... an important drug for the treatment of schizophrenia. ... quetiapine was listed in the Catalogue of Drugs ...
(Date:8/28/2015)... -- IP Shakti, LLC, today announced that it has changed its ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... signifies our transformation into a company focused on patent claim ... claim validity." ... platform, the Company commenced a corporate re-branding initiative in order ...
(Date:8/28/2015)... Korea , Aug. 28, 2015 ... University and Dr. Ra from Biostar , Published ... Confirmed 30% increase of lifespan through multiple IV administration ... physical vitality, and life expectancy found , Commercialization ... Korea have determined the possibility that adult mesenchymal stem ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
Inquire...
The Perfect Vac Quad Manifold allows one to four 96-well plates to be processed simultaneously. A single plate may be processed in 30 minutes; four plates are processed in 45 minutes....
... Rotary, Vacuum-Style and Nitrogen Blow-Down Evaporators. For over ten years TurboVap concentration technology has received enormous acclaim ... ... ... ...
The Empore 96 well plate vacuum manifold comes complete with waste tray, gasket and shims, may be used as a stand-alone or with 96-well automation....
Medicine Products: